These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21263104)

  • 1. Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies.
    Barzilay JI; Gao P; O'Donnell M; Mann JF; Anderson C; Fagard R; Probstfield J; Dagenais GR; Teo K; Yusuf S;
    Arch Intern Med; 2011 Jan; 171(2):142-50. PubMed ID: 21263104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Normoalbuminuria at all costs?].
    Maggio M
    G Ital Nefrol; 2011; 28(4):354. PubMed ID: 21809300
    [No Abstract]   [Full Text] [Related]  

  • 3. [Should normotensive diabetic patients with microalbuminuria be treated with angiotensin converting enzyme inhibitors?].
    Feldt-Rasmussen BF
    Ugeskr Laeger; 2002 Apr; 164(14):1907-9. PubMed ID: 11957423
    [No Abstract]   [Full Text] [Related]  

  • 4. ONTARGET still OFF-TARGET?
    Lambers Heerspink HJ; de Zeeuw D
    Circulation; 2011 Mar; 123(10):1049-51. PubMed ID: 21357820
    [No Abstract]   [Full Text] [Related]  

  • 5. Methodological issues in the assessment of cognitive decline in ONTARGET and TRANSCEND.
    Odili AN; Richart T; Staessen JA
    Lancet Neurol; 2011 Jan; 10(1):22-4. PubMed ID: 21067977
    [No Abstract]   [Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials.
    Tocci G; Paneni F; Palano F; Sciarretta S; Ferrucci A; Kurtz T; Mancia G; Volpe M
    Am J Hypertens; 2011 May; 24(5):582-90. PubMed ID: 21331058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study.
    Ravid M; Lang R; Rachmani R; Lishner M
    Arch Intern Med; 1996 Feb; 156(3):286-9. PubMed ID: 8572838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).
    Dalla Vestra M; Pozza G; Mosca A; Grazioli V; Lapolla A; Fioretto P; Crepaldi G
    Diabetes Nutr Metab; 2004 Oct; 17(5):259-66. PubMed ID: 16295047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is microalbuminuria a disease?
    Williams CD
    Pharmacotherapy; 2012 Sep; 32(9):781-3. PubMed ID: 22949141
    [No Abstract]   [Full Text] [Related]  

  • 10. Who is tested for diabetic kidney disease and who initiates treatment? The Translating Research Into Action For Diabetes (TRIAD) Study.
    Johnson SL; Tierney EF; Onyemere KU; Tseng CW; Safford MM; Karter AJ; Ferrara A; Duru OK; Brown AF; Narayan KM; Thompson TJ; Herman WH
    Diabetes Care; 2006 Aug; 29(8):1733-8. PubMed ID: 16873772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAS blockade: new possibilities in the treatment of complications of diabetes.
    Ruilope L
    Heart; 2000 Sep; 84 Suppl 1(Suppl 1):i32-4:discussion i50. PubMed ID: 10956319
    [No Abstract]   [Full Text] [Related]  

  • 12. The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency.
    Tong PC; Ko GT; Chan WB; Ma RC; So WY; Lo MK; Lee KF; Ozaki R; Chow CC; Cockram CS; Chan JC
    Diabetes Obes Metab; 2006 May; 8(3):342-7. PubMed ID: 16634995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers on long-term outcome of catheter ablation for atrial fibrillation.
    Tayebjee MH; Creta A; Moder S; Hunter RJ; Earley MJ; Dhinoja MB; Schilling RJ
    Europace; 2010 Nov; 12(11):1537-42. PubMed ID: 20682557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on heart rate variability of metoprolol supplementary to ongoing ACE-inhibitor treatment in Type I diabetic patients with abnormal albuminuria.
    Ebbehøj E; Poulsen PL; Hansen KW; Knudsen ST; Mølgaard H; Mogensen CE
    Diabetologia; 2002 Jul; 45(7):965-75. PubMed ID: 12136395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin converting enzyme inhibitors in diabetic patients with microalbuminuria or normoalbuminuria.
    Viberti G; Chaturvedi N
    Kidney Int Suppl; 1997 Dec; 63():S32-5. PubMed ID: 9407417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preserving the diabetic kidney.
    Poirier SJ
    J Fam Pract; 1998 Jan; 46(1):21-7. PubMed ID: 9451365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes.
    Donnelly R; Yeung JM; Manning G
    J Hypertens Suppl; 2003 Mar; 21(1):S7-12. PubMed ID: 12769161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of enalapril and nitrendipine on exercise albuminuria in normotensive type I diabetic patients with incipient nephropathy.
    Heinemann L; Janicke I; Bender R; Berger M; Sawicki PT
    Horm Metab Res; 1996 Oct; 28(10):549-52. PubMed ID: 8934214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.